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Abstract
Background: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are serious and growing health
problems with enormous impact on psychological and social functioning. Despite high rates of comorbid depression
and anxiety in these patient populations, and the adverse impact these have upon treatment adherence, quality of life,
social connectedness and healthcare costs there has been little attention focused on the prevention or management
of these problems. Thus, our aim was to evaluate the Dialysis Optimal Health Program (DOHP) that adopts a person-
centred approach and engages collaborative therapy to educate and support those diagnosed with ESKD who are
commencing dialysis.
Methods: The study design is a randomised controlled trial. Ninety-six adult patients initiating haemodialysis or
peritoneal dialysis will be randomly allocated to either the intervention (DOHP) or usual care group. Participants receiving
the intervention will receive nine (8 + 1 booster session) sequential sessions based on a structured information/workbook,
psychosocial and educational supports and skills building. The primary outcome measures are depression and anxiety
(assessed by the Hospital Anxiety and Depression Scale; HADS). Secondary outcomes include health-related quality of life
(assessed by the Kidney Disease Quality of Life instrument; KDQOL), self-efficacy (assessed by General Self-Efficacy Scale)
and clinical indices (e.g. albumin and haemoglobin levels). Cost-effectiveness analysis and process evaluation will also be
performed to assess the economic value and efficacy of the DOHP. Primary and secondary measures will be collected at
baseline and at 3-, 6-, and 12-month follow-up time points.
Discussion: We believe that this innovative trial will enhance knowledge of interventions aimed at supporting patients in
the process of starting dialysis, and will broaden the focus from physical symptoms to include psychosocial factors such
as depression, anxiety, self-efficacy, wellbeing and community support. The outcomes associated with this study are
significant in terms of enhancing an at-risk population’s psychosocial health and reducing treatment-related costs and
associated pressures on the healthcare system.
Trial registration: ANZCTR no. 12615000810516. Registered on 5 August 2015.
Keywords: Dialysis, Chronic kidney disease, Collaborative therapy, End-stage kidney disease, Psychosocial health,
Randomised controlled trial
Abbreviations: AQoL-6D, Assessment of Quality of Life-6 dimensions; Brief-IPQ, Brief Illness Perception Questionnaire;
Brief COPE, abbreviated version of the COPE Inventory; CEQ, Credibility/Expectancy Questionnaire; CKD, chronic kidney
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of Life; MINI, Mini-International Neuropsychiatric Interview; MMRM, mixed-effects model, repeated measures; OHP, Optimal
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Short Form; TIPI, Ten-Item Personality Inventory; TRIPOD, Translating Research, Integrated Public Health Outcomes and
Delivery; WSAS, Work and Social Adjustment Scale
Background
Escalating prevalence and incidence rates of chronic
kidney disease (CKD) and end-stage kidney disease
(EKSD) are a global challenge [1]. In 2012, around 10 %
of Australians (1.7 million) aged 18 and over exhibited
measured biomedical signs of CKD; of these, 97 %
showed early signs of CKD (stages 1–3) [2]. The overall
prevalence of Australians aged 25 and over with ESKD
has increased by approximately 20 % from 2005 to 2010
[3]. Dialysis is a challenging experience for most pa-
tients, especially in the first year [4–6], with high eco-
nomic and personal costs to patients and their families,
and considerable economic and planning implications
for the healthcare system [7]. Commonly reported symp-
toms of CKD and ESKD include: loss of appetite; insom-
nia; high blood pressure; and swelling of feet and ankles.
Consequently, the disease burden on quality of life is sig-
nificant [1]. Thus, the patient and family find themselves
dealing with multiple disease-associated stressors includ-
ing balancing the restrictions of this disease within the
context of their intimate relationships, families, social
networks, treatments, and cultures. Psychological dis-
tress, as in other chronic physical diseases, is common
in individuals with CKD and ESKD with rates consider-
ably above those in the general population [8–12]. The
randomised controlled trial (RCT) described here will
adopt a person-centred approach combining collabora-
tive therapy and care coordination to support and im-
prove the psychosocial health and quality of life of those
living with CKD and ESKD.
CKD/ESKD psychosocial interventions
In addition to the increased risk of hospitalisation in
ESKD patients with comorbid mental health issues [13],
several studies have reported the effect of depression on
chronic haemodialysis patient survival to be of similar
magnitude to that of medical risk factors [14, 15]. The
mechanisms linking depression with survival in this
population are unclear but may be related to factors
such as treatment adherence, nutritional issues, percep-
tions of illness, personality, coping styles and increased
perception of social support. Adverse biological conse-
quences of the depressed state, including inflammatory,
autonomic and neuroendocrine effects also play a role
[10]. Psychological distress may also influence a patient’s
decision to withdraw from dialysis, accepting palliation,
with a recent study finding depression to be significant
factor in this decision, particularly where symptoms are
apparent in the early stages after commencement of
dialysis [14].
A recent review of self-management programs in CKD
identified weak evidence that their delivery alone can
improve adherence [16]. The authors of that review con-
cluded that life contexts, socioeconomic factors, health
literacy and psychological factors, as well as communica-
tion with healthcare providers, all contribute to an indi-
vidual’s adherence to treatment. For example increased
psychological distress and poorer communication with
healthcare providers was associated with reduced treat-
ment adherence. This review further identified that
self-efficacy skill building could potentially improve ad-
herence and therefore be a target for psychosocial in-
terventions [16]. In addition, social processes such as
social support can influence psychological changes at
an individual level, which may then lead to modified
health behaviours. Psychosocial factors are important
because they enhance quality of life, in turn slowing the
progression of various chronic diseases [17].
The burden and role of depression, anxiety, quality of
life and social support in adults with CKD prior to renal
replacement therapy was examined in a recent review of
the literature [18]. Although the evidence for the impact
of psychosocial factors was sparse, the authors did iden-
tify that depression and depressive symptoms may inde-
pendently predict progression to dialysis, hospitalisation
and death [18]. However, investigations into the impact
of anxiety disorders, social support and quality of life on
the clinical course of CKD have received minimal at-
tention. The authors recommended large-scale pro-
spective cohort studies to clarify the burden and
prognostic impact of psychosocial factors in this vul-
nerable population [18].
Although psychosocial interventions are effective in
the treatment of anxiety and depression, they have not
yet been deployed or evaluated in the ESKD population.
To date, there have been no published randomised con-
trolled trials assessing the efficacy of psychosocial inter-
ventions for improving depression in ESKD, albeit there
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is some clinical evidence that these interventions might
be effective [19, 20].
Translating Research, Integrated Public Health Outcomes
and Delivery (TRIPOD)
This RCT is part of a larger research program – TRI-
POD – which will evaluate our Optimal Health Program
(OHP) across three chronic conditions; namely CKD/
ESKD, diabetes mellitus and stroke, inclusive of cost-
effectiveness analyses. Based on a collaborative therapy
framework (CTF; consists of three core components -
education relating to factors that influence mental
health, coping strategies that help manage stress and ad-
justment to illness, and skills development to manage
stress, illness and long-term optimal health) the OHP
was originally developed to support people with mental
illness [21]. The initial trial, in an adult mental health
service, demonstrated significant improvements in
health and social functioning, a reduction in hospital
admissions and net cost savings per patient [22]. A key
aspect of collaborative therapy is recognising that ‘recov-
ery’ and chronic models of health care are not dichotom-
ous [23]. With the intention of enhancing self-efficacy,
self-management, care co-ordination and quality of life,
the OHP has been adapted within the broader context of
chronic disease. Thus, in the current series of trials our
OHP is used to implement this therapeutic framework
to enable clinicians and consumers to work systematic-
ally towards the achievement of optimal psychosocial
health outcomes within mainstream health services. The
self-management foundations of the OHP are particu-
larly relevant for adults with ESKD who face the daily
challenge of managing various and often simultaneous
aspects of their disease such as managing multiple medi-
cations, fluid and food intake, ongoing appointments,
and monitoring of blood pressure as well as coping with
the emotional impact of their care regimen. This proto-
col describes an RCT to evaluate a dialysis optimal
health program (DOHP), a program specifically designed
for people living with stage 5 CKD/ESKD.
DOHP pilot studies
Adaptation of the OHP for people with ESKD was in-
formed by clinical evidence, a review of the associated
literature, and pilot data. Two studies, both conducted
at St Vincent’s Hospital (Melbourne) were initially con-
ducted that provided (1) information to assist with the
development of DOHP and (2) evidence as to the feasi-
bility of DOHP. The first study was a cross-sectional
survey of 27 adult patients receiving either haemodialysis
or peritoneal dialysis. The aim of this study was to ex-
plore the impact of ESKD on individual illness percep-
tions, coping styles and psychological wellbeing. Key
findings indicated that perceptions of illness rather than
actual symptoms best accounted for patients’ adaptation
to ESKD. Given that the focus of the OHP is to support
the patient’s psychological wellbeing, using strategies to
improve self-efficacy, empower patients and enhance
their self-management skills, these initial findings pro-
vided evidence for the suitability of an adaptation of the
OHP to those experiencing ESKD and initiating dialysis.
Pilot data was also collated via a RCT (n = 12) of the
DOHP versus standard care. Patients from a metropol-
itan and a rural dialysis service were followed over a 12-
month period from initiation of dialysis. There were two
deaths and one further withdrawal, leaving nine patients
who completed the study. Primary outcomes were de-
pression and anxiety. Secondary outcomes included
quality of life, treatment adherence, perceived social sup-
port, level of function, episodes of psychiatric illness and
treatment, medical morbidity and health care utilisation
(e.g. outpatient visits; hospitalisations) [10]. An analysis
of incidence of depression and anxiety, based on regular
face-to-face and phone call assessments using the Mini-
International Neuropsychiatric Interview (MINI 6.0)
[24], identified incidents of depression and anxiety in the
control group only (depression × 3; anxiety × 4). Due to
the small size of the trials, conclusions regarding the po-
tential benefit of OHP in relation to the primary and
secondary outcomes were not able to be made. However,
in relation to the feasibility of the trial, it was clear from
participant feedback that the OHP program was associ-
ated with high satisfaction, perceived development of
skills to effectively manage problems, and would be
recommended by others [10].
Research aims
The aim of this research is to determine whether a
dialysis-specific OHP (DOHP) will improve the psycho-
social health of dialysis patients, compared to usual care.
The primary objective is to identify the impact of DOHP
on levels of depression and anxiety in those receiving
dialysis. Secondary objectives are to evaluate the impact
of DOHP on quality of life, self-efficacy, social and work-
place functioning, self-management, and illness percep-
tions of and coping with ESKD.
A full economic evaluation, namely, cost-effectiveness
analysis will be performed to provide further evidence on
the efficiency of the DOHP by outweighing health gain and
impact on the use of health resources associated with
DOHP. The perspectives are from the Australian healthcare
system and the patient/family. Quality-adjusted life years
(QALYs) will be measured using the Assessment of Quality
of Life-6D (AQoL-6D) [25] and European Quality of Life-5
dimensions (EQ-5D-3L) [26]. Process evaluation including
focus group interviews will also be conducted with patient
and staff participants to assess the effectiveness of the
DOHP, implementation, and uptake and service delivery.
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Methods
General design
This is a prospective randomised controlled trial to
evaluate the effectiveness and cost-effectiveness of the
OHP specifically adapted for patients receiving dialysis.
The DOHP will be delivered as a 9- (8 + 1) week indivi-
dualised support program using health promotion strat-
egies and will be compared to usual care. Assessments
will take place at baseline, 3, 6, and 12 months post-
baseline. The study protocol was approved by the St
Vincent’s Hospital Human Research Ethics Committee
(HREC-A 019/14). An executive steering committee
consisting of a nephrologist, a specialist renal nurse, psy-
chologists, psychiatrists, nurses and a health economist
oversees project planning, procedures and ongoing data
collation.
Setting
The study will be conducted at the nephrology unit of St
Vincent’s Hospital, a large metropolitan teaching hos-
pital in Melbourne, Australia. As of March 2015, the dia-
lysis unit had 290 patients with ESKD receiving dialysis
and 190 referred for medical management of CKD with
treatment aim of preserving kidney function. The neces-
sary volume of clinical cases and expertise required for
this study was established within St Vincent’s nephrology
unit in the piloting phase of this research.
Participants
A minimum of 96 patients initiating dialysis will be re-
cruited into the study. The type of dialysis is haemodi-
alysis, peritoneal dialysis or home dialysis, or collectively
known as ‘dialysis’. The following criteria must be met
for inclusion in the study: (1) diagnosis of near ESKD
confirmed by medical records; (2) expected to com-
mence maintenance dialysis for the first time in the next
3 months or commencement of dialysis in the past
3 months; (3) aged 18 or above; and (4) able to converse
in English without an interpreter. Exclusion criteria are:
(1) presence of developmental disability or amnestic syn-
drome impairing their ability to learn from the interven-
tion; (2) participants returning to dialysis following a failed
renal transplant; and (3) comorbid serious illness as de-
fined by the treating physician. Individuals who are seeking
a mental health professional or taking psychotropic medi-
cations will not be excluded from participating.
Power was calculated to detect a medium effect size of
d = 0.40 using a sample size formula comparing time-
averaged differences for continuous outcomes in repeated
measurement studies [27]. The power calculations as-
sumed the following: (a) two primary outcome measures
(HADS anxiety and depression severity scores); (b) four
assessment points (i.e. baseline, 3, 6, and 12 months); (c) a
between-repeated measures ρ = 0.70; (d) a study-wide type
I error of 0.05 (i.e. a single test α of 0.05 ÷ 5 or 0.01); (f) a
type II error rate (β) of 0.20 (power of 0.80); and (g) two-
tailed statistical tests. The within-subject correlation (0.70)
was based upon a previous OHP trial that demonstrated
high correlations over time [22]. The power analysis indi-
cated that 38 participants would be required in each
group. Allowing for an attrition rate of 20 %, a total of 96
participants, or 48 in each arm, will be recruited.
Study procedures
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. All eligible participants will be
fully informed that they are being asked to participate in
an RCT. The procedures involved in the study, and the
chances of being assigned randomly to one of two
groups will be explained verbally and via an information
sheet approved by St Vincent’s Hospital Human Re-
search Ethics Committee. A signed consent form will be
obtained from each participant. Participants will be
made aware of their right to withdraw from the study at
any time with no impact on usual clinical care received.
Randomisation and blinding
Following the initial screening and gaining of consent,
participants will be allocated to either intervention or
control group via a computer-generated block random-
isation sequence created by an independent person not
directly involved in the study. Due to the nature and
length of the intervention, it is not possible to blind either
patient or investigator to the intervention allocation.
Recruitment
Potential participants will be identified by dialysis clin-
ical staff based on diagnosis and inclusion criteria and
provided with a flyer and verbal explanation. Study fliers,
including contact details for the research team, will also
be posted online through community organisations. Par-
ticipants from the community may contact researchers
directly to request further information. If agreeable,
patients will be informed and formally consented by a
research assistant (not associated with the patient’s treat-
ment team) and allocated to either the intervention or
control group. CONSORT procedures will be followed
throughout the study to ensure the minimum set of rec-
ommendations for reporting randomized trials [28].
Participants will be recruited over a 24-month period
(see Fig. 1).
Intervention: DOHP
The DOHP is delivered in nine (8 + 1 booster session)
sequential sessions based on a structured workbook. The
workbook is central to learning, (i) providing detailed in-
formation on the contents of each session and (ii) acting
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as a health journal where participants can record key
dates, appointments, contacts and medication details.
Participants are encouraged throughout the program to
identify areas of kidney disease or specific concerns
upon which they would like to focus. Sessions are ap-
proximately 1 hour in duration and held weekly, apart
from the ‘booster’ session, which is held 3 months after
session 8. Each participant will be allocated to one OHP
trained facilitator who will administer the suite of ques-
tionnaires, taking approximately 25 minutes to complete,
and conduct the intervention. Learning is cumulative
with each session designed to build on the previous ses-
sion including tasks to complete between sessions, such
as coping strategies (e.g. breathing exercises).
As the DOHP adopts a holistic collaborative care ap-
proach it is not the intention to prevent or treat depres-
sion directly, but rather to identify the impact it has on
the psychosocial health of patients undergoing dialysis
as per the nine sessions as outlined below. In summary,
session 1 introduces the DOHP within the six domains
of ‘optimal health’; considering the balance of mental,
emotional, social, occupational, physical and spiritual
needs of a person. This session provides participants
with the opportunity to explore and understand their
dialysis self-management behaviour from a holistic per-
spective. Sessions 2 and 3 initiate development of a
health plan exploring the implications and potential
complications of renal failure and dialysis in terms of
strengths and vulnerabilities in session 2, and under-
standing and monitoring disease impact in session 3
(e.g. the effects of stress on high blood pressure). The
focus of session 4 is on metabolic monitoring and medi-
cation management (e.g. blood pressure medication and
low potassium diet). Session 5 expands the health plan
to include key renal failure treatment partnerships and
supports in the community and online (e.g. other
patients, family, online forums). Session 6 focuses on
change enhancement in terms of understanding past
Inclusion criteria met
Informed consent and baseline assessment
Randomization
DOHP Intervention n=48
baseline assessment
Control group (usual care) n=48
baseline assessment
3-month follow-up assessment 
Assessment of eligible dialysis patients (24 months)
6-month follow-up assessment 
12-month follow-up assessment
Excluded from study
Declined to participate
Fig. 1 Flowchart of the Dialysis Optimal Health Program (DOHP) randomized controlled trial (RCT)
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events and establishing new proactive avenues for
change. The aim of session 7 is goal setting via creative
problem solving and planning around the complexities
of renal failure and dialysis. Session 8 strategises well-
being maintenance and sustainability related to the dia-
lysis treatment. The objective of the ‘booster session’
(session 9) is to consolidate progress via reviewing health
plans and reflecting on achievements made toward
health-related goals. An additional table provides further
detail of sessions including behaviour change techniques
(see Additional file 1).
A health professional (e.g. nurse, psychologist) trained
in the collaborative therapy approach (2-day workshop
plus regular supervision and fidelity checks) will facili-
tate each session. The facilitator will draw on CKD/
ESKD-specific information in concordance with individ-
ual circumstances. Examples include coping strategies
for addressing anxiety related to self-monitoring of
blood pressure, availability of community supports, and
dealing with the stress of adapting to ESKD and initiat-
ing dialysis. Emphasis is placed on the collaboration be-
tween facilitator and participant to achieve goals that
stem from the participant’s intrinsic concerns and needs.
Health promotion is also a major focus, hence the facili-
tator will encourage participants to identify early warn-
ing signs of stress and illness and integrate healthy
coping strategies to prevent the build-up of stress. In
conjunction with the multidisciplinary team, facilitators
will coordinate visits and discuss and arrange referrals to
other services depending on participant needs. Further,
if at any time during the study a participant identified
severe anxiety and/or depression or suicidal ideation
they will be contacted by a senior clinician of the re-
search team and where relevant, referred to an appropri-
ate mental health service. Patient participation may be
discontinued based upon self-request and/or feedback
from the referred treating mental health service. Partici-
pants residing in rural and regional areas will have the
option of participating in sessions via telephone or Skype
(depending on patients’ access to the internet).
Standard care
Participants randomised into the standard care condition
will receive medical care consistent with patients who
have ESKD. This will include regular medical appoint-
ments with medical staff, diagnostic tests (e.g. blood glu-
cose levels) and access to treatments based upon disease
status and recommendations by treating hospital staff.
Outcome measurements
Primary and secondary outcomes will be assessed at
baseline, 3, 6 and 12 months (see Table 1). Primary mea-
sures are changes in symptom severity of anxiety and
depressive disorders as assessed by the Hospital Anxiety
and Depression Scale (HADS) [29]. Secondary measures
are: quality of life, as assessed via a disease-specific meas-
ure the Kidney Disease Quality of Life (KDQoL) [30] and
health-related quality of life as assessed by the Assessment
of Quality of Life (AQoL-6D) [25] and European Quality
of Life-5 dimensions (EQ-5D-3L) [26] (both scales are
highly cited, AQoL with Australian norms allowing com-
parison); self-efficacy measured by the General Self-
Efficacy Scale (GSE) [31], a general sense of perceived self-
efficacy in regarding daily hassles as well as adaptation to
stressful life events; illness perceptions measured by the
Brief Illness Perception Questionnaire (Brief-IPQ) [32], an
assessment of cognitive and emotional representations of
illness; coping strategies as measured by an abbreviated
version of the COPE Inventory [33], the Brief COPE [34];
a 10-item measure of the Big Five personality dimensions
[35]; and impact of a person’s mental health difficulties on
their ability to function via the Work and Social Adjust-
ment Scale (WSAS) [36]; treatment expectancy and ra-
tionale credibility in clinical studies as assessed by the
Credibility/Expectancy Questionnaire (CEQ) [37]; per-
ceived acceptability of treatment, assessed using the Treat-
ment Evaluation Inventory-Short Form (TEI-SF) [38];
clinical indices such as albumin and haemoglobin levels
and Kt/V (dose of dialysis); and health care utilisation for
economic evaluation purposes assessed by the Health
Table 1 Primary and secondary outcome assessments and time
points for Dialysis Optimal Health Program (DOHP)
Assessment tools Baseline 3-month 6-month 12-month
Primary outcomes
HADS (14 items) X X X X
Secondary outcomes
AQoL-6D (20 items) X X X X
Brief COPE (28 items) X X X X
Brief-IPQ (9 items) X X X X
CEQ (6 items) X
Clinical indices (e.g. Kt/V) X X X X
EQ-5D-3L (6 items) X X X X
GSE (10 items) X X X X
HCUQ (17 items) X X X X
KDQoL (24 items) X X X X
TEI-SF (9 Items) X
TIPI (10 items) X
WSAS (5 items) X X X X
HADS Hospital Anxiety and Depression Scale [29], AQoL-6D Assessment of
Quality of Life-6 Dimensions [25], Brief COPE [34] abbreviated version of the
COPE Inventory [33], Brief-IPQ Brief Illness Perception Questionnaire [32], CEQ
Credibility/Expectancy Questionnaire [37], EQ-5D-3 L European Quality of Life-5
Dimensions-3 Levels [26], GSE General Self-Efficacy Scale [31], HCUQ Health Care
Utilisation Questionnaire [39], KDQoL Kidney Disease Quality of Life [30], TEI-SF
Treatment Evaluation Inventory-Short Form [38], TIPI Ten-Item Personality
Inventory [35], WSAS Work and Social Adjustment Scale [36]
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Care Utilisation Questionnaire (HCUQ) [39]. Scoring and
interpretation of all questionnaires will be undertaken
using the recommended published procedures outlined by
the relevant questionnaire authors. Adherence to the
intervention will be recorded in sessions 2 to 9 by the pro-
gram facilitators as participants provide feedback on their
uptake of the DOHP in the time between each session.
Regarding outcome measurement for the cost-effectiveness
analysis the utility measurements of generating quality of life
will be assessed using AQoL-6D [25] developed in Australia
and the EQ-5D [26]. Regarding cost, health care utilisation of
the patient will be collected from the medical records
at St Vincent Hospital for inpatient use (patient con-
sent obtained) and by self-administered Health Care
Utilisation Questionnaire (HCUQ) [39] for inpatient
use other than St Vincent Hospital and all outpatient
and community health care use from the patient at
baseline and each of the follow-up visits. The sources
of the price information are from MBS (Medical Benefit
Schedule), PBS (Pharmaceutical Benefit Scheme) and
other Australian governmental documents. Both health-
care outcomes and costs will then be compared be-
tween participants in intervention and control groups
using the incremental cost-utility ratio which indicates
the incremental cost per QALY (quality-adjusted life
year) of this intervention within the trial period. The
estimated long-term (lifetime) impact on cost and ef-
fectiveness of the intervention beyond the trial period
will be extrapolated using Markov process modelling. The
Markov process model will be constructed in reflecting
the evolving and progressing of the health state of patients
with CKD and ESKD, including the health state of, for ex-
ample, relapse of depression and anxiety. Appropriate sen-
sitivity analysis for the best and worst scenarios will also
be performed based on key variables such as the probabil-
ities of relapse of depression and anxiety to examine the
robustness of the cost-effectiveness result.
Due to variability of usual care in the control group,
key aspects of standard care will be assessed via re-
sponses to the HCUQ [39]. Medical records will also be
accessed to confirm diagnostic information, inpatient,
outpatient and emergency department visits.
Program assessment and intervention fidelity
The DOHP facilitators will receive training, a structured
manual/protocol and regular supervision (fortnightly with
clinical investigators) to discuss any concerns and to en-
sure standardised delivery of the intervention. Any issues
raised by participants can also be discussed at supervision
meetings. Sessions will be audio recorded and rated by
members of the research team to assure fidelity of the
intervention (i.e. does the content of each session accur-
ately reflect the stated content and session plan). Further,
an expert of OHP not part of the research team will also
randomly sample 10 % of the case notes to ensure sessions
conducted comply with OHP session content and proce-
dures. Any variations from the protocol will be fed back to
facilitators.
Post-intervention focus groups will be held for clini-
cians and for participants. The purpose of the focus
groups is to gain an in-depth understanding of their ex-
periences of the DOHP, advantages and disadvantages of
conducting the DOHP within existing services (for ser-
vice providers), and suggestions for further components
to include or to exclude.
Statistical analyses
Intention-to-treat analysis will be employed to prevent
overestimation of intervention efficacy. Categorical vari-
ables will be analysed using chi-squared tests (or Fisher’s
exact test for small samples). A mixed-effects model, re-
peated measures (MMRM) approach will be used to exam-
ine the longitudinal profile of the two primary outcome
measures at the three time points (3, 6 and 12 months
post-baseline). For all MMRM analyses, baseline scores
will be used as covariates and the models will include pre-
specified fixed effects of treatment, clinician and time, in
addition to treatment-by-time and treatment-by-clinician
interactions. Appropriate adjustments for multiple primary
(depression and anxiety) tests will be made, i.e. Bonferroni
correction to ensure the risk of type I error is maintained
at 5 %. The potential impact of any additional care re-
ceived by some participants will be assessed in a separate
regression analysis using analysis of covariance.
Secondary analyses using analysis of covariance will be
conducted to compare change scores during treatment and
follow-up points for primary, secondary and process out-
comes using the fixed, continuous covariate of baseline
score as well as the categorical fixed effects of treatment
group, clinician and treatment-by-clinician interactions.
Following this, all secondary outcome measures will be
assessed, as per above using first a MMRM and then asses-
sing change scores.
Although the attrition rate is not expected to vary by
group (intervention vs usual care), we will attempt to iden-
tify key predictors of attrition status (i.e. demographic or
clinical baseline characteristics) and test for differences be-
tween groups. Assuming the data are missing at random,
several procedures offer effective approaches that may
attenuate attrition. For example, multiple imputation
procedures that utilise the expectation-maximization
(EM) algorithm with bootstrap estimates of standard
errors will be used. A maximum likelihood model with
time as a random variable will allow the use of all avail-
able data from all assessments, reducing bias and in-
creasing power [40]. Application of these procedures
has been shown to provide unbiased estimates, even in
the face of substantial missing data [41].
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Discussion
CKD and ESKD are both serious and growing health
problems that have enormous impact on social and
psychological functioning [4–15]. Despite high rates of
comorbid depression and anxiety in these patient popu-
lations, as well as disquieting evidence of their potential
effects on intervention adherence, quality of life, social
connectedness and healthcare costs, there has been little
development in the area of prevention or management
of these conditions [19, 20]. This trial of an 8 + 1 week
psychosocial intervention aimed at improving depression
and anxiety with further subsequent psychosocial impli-
cations will be the first of its kind undertaken in the
CKD transitioning to ESKD with dialysis population.
The DOHP has several strengths, primarily the provision
of coordinated care aimed at enhancing the psychosocial
health of patients experiencing ESKD. We believe that this
innovative trial will contribute to the knowledge of inter-
ventions aimed at supporting this patient population and
will broaden the focus from symptoms to include psycho-
social factors such depression, anxiety, self-efficacy, well-
being and community supports. In addition, we envisage
the quality control component of this trial, via process
evaluation, will offer further insight into how the interven-
tion can best be adapted and integrated into the general
medical setting.
The outcomes associated with this project are signifi-
cant in terms of enhancing an at-risk population’s quality
of life and psychological wellbeing as well as reducing
real treatment-related costs and associated pressures on
the renal healthcare system. Furthermore, the proposed
RCT will aim to address and reflect the key intent of this
major research initiative; a multifactorial, long-term
collaborative approach developed via end-user-driven re-
search partnerships that will deliver health benefits to en-
able Australians with ESKD to age well and productively.
Trial status
Patient recruitment was ongoing at the time of manu-
script submission. Data collection will continue until at
least December 2017.
ANZCTR no. 12615000810516.
Additional file
Additional file 1: This table “DOHP Sessional and Behaviour Change
Techniques with Theoretical Framework” provides details of the intervention
sessions and related behavioural change techniques. (DOCX 37 kb)
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